The Europe kidney cancer therapeutics diagnostics market size was USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031, expanding at a CAGR of 5.7% during 2023–2031. The growth of the market is attributed to rising number of kidney cancer cases in the region.
Moreover, increasing research and development expenditure of the pharmaceutical companies is driving the market growth. One of the common symptoms of kidney cancer includes blood in urine, which may appear dark red, orange, or pink in color. As kidney cancer progresses, it may produce other symptoms, such as persistent pain or pressure below the ribs and intense fatigue.
Kidney cancer is the seventh most common cancer in the UK, which is responsible for around 12,600 new cases every year in the country, which equates to 34 cases every day and up to 30% of all people are diagnosed in the advanced stage of the disease. Over the last decade, kidney cancer incidence has risen by 47% and is projected to rise by 26% in the UK between 2014 and 2035.
Kidney cancer progression is diversified through four grade levels. Grade one kidney cancers have cells looking same as normal kidney cells, while cancer cells that look very different from normal cells are given a higher grade as they tend to grow faster than grade one kidney cells.
Market Trends, Drivers, Restraints, and Opportunities:
-
Increasing use of imaging techniques such as computerized tomography (CT) scans for diagnosing cancers is expected to contribute to the growth of the global Europe kidney cancer therapeutics diagnostics market.
-
Various options available for the treatments and presence of many drugs in pipeline are expected to augment the market growth.
-
Lack of awareness about the prevalence of kidney cancer can restraint the market growth.
-
The outbreak of COVID-19 has negatively impacted the Europe kidney cancer therapeutics diagnostics market. However, the market is anticipated to recover soon.
-
Increasing prevalence of kidney cancer is anticipated to increase the drug demand, propelling the growth of the market during the forecast period.
Scope of Europe Kidney Cancer Therapeutics Diagnostics Market Report
The report on the Europe kidney cancer therapeutics diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Kidney Cancer Therapeutics Diagnostics Market - Europe Industry Analysis, Growth, Share, Size, Trends, And Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Cancer Types (Clear cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma, Others), Components (Drugs and Diagnostics)
|
|
Geographical scope
|
Germany, United Kingdom, France, Italy, Spain, and Rest of Europe
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, BRISTOL-MYERS SQUIBB COMPANY, Amgen Inc, Novartis AG, Pfizer Inc, and Seattle Genetics
|
Europe kidney cancer therapeutics diagnostics Market Segment Insights:
Clear cell RCC segment to grow at a rapid pace
Based on cancer types, the market is divided into clear cell RCC, papillary RCC, chromophobe RCC, urothelial carcinoma, and others. The clear cell RCC segment is anticipated to account for a key share and is anticipated to grow at a steady rate during the forecast period.
Clear cell RCC is the most common type of kidney cancer and makes up about 80% of all renal cell carcinoma (RCC) cases. Clear cell RCC is more common in adults than in children. Renal cell carcinoma makes up 2% to 6% of childhood and young adult kidney cancer cases.
Diagnostics segment to account a major market share
Based on components, the market is divided into drugs and diagnostics. The diagnostics segment is anticipated to account for a major share due to high prevalence of the disease, presence of diagnostic procedures and various treatment therapies, higher income levels in the region, rising preventive testing, and increasing number of healthcare and insurance services.
The United Kingdom to account a large market share
On the basis of geography, the market is segregated into Germany, United Kingdom, France, Italy, Spain, and Rest of Europe. The UK to account for a large market share during the forecast period. Rising prevalence of cancer and presence of reimbursement scenario are driving the growth of the market in the country. However, the market in Germany is expected to register substantial growth during the forecast period.
Segments
The global Europe kidney cancer therapeutics diagnostics has been segmented on the basis of
Cancer Types
- Clear cell RCC
- Papillary RCC
- Chromophobe RCC
- Urothelial Carcinoma
- Others
Components
Key Players
- Abbott Laboratories
- Bayer AG
- F. Hoffmann-La Roche Ltd
- BRISTOL-MYERS SQUIBB COMPANY
- Amgen Inc
- Novartis AG
- Pfizer Inc
- Seattle Genetics
Competitive Landscape
The major players of the market are Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, BRISTOL-MYERS SQUIBB COMPANY, Amgen Inc, Novartis AG, Pfizer Inc, and Seattle Genetics.
Companies are focusing on innovation, expansion, and acquisitions to expand their market share.
Request For Customization
Enquiry Before Buying
Speak With Analyst
